Mathew Vincent of ACT on hESC derived RPE cells – at Stem Cells USA

Posted: December 21, 2012 at 11:43 am




Mathew Vincent of ACT on hESC derived RPE cells - at Stem Cells USA RM Congress 2012
Mathew Vincent, Director of Business Development at Advanced Cell Technology, spoke at the Stem Cells USA Regenerative Medicine Congress 2012 on the topic, #39;Meaningful clinical results with hESC derived RPE cells in patients with SMD and Dry AMD. #39; The Stem Cells Regenerative Medicine Congress is where pharma, biotech, academia, government and investors come to uncover the technologies, strategies and business models that will help get stem cell and regenerative medicine treatments to market faster and more cost effectively. For more information, go to http://www.terrapinn.com/stemcellsusa. Or, check out our blog at blogs.terrapinn.com/total-biopharma for up to date information on the stem cells, RM and cord blood banking and therapeutics sectors.From:biopharmachannelViews:0 0ratingsTime:25:03More inScience Technology

Continued here:
Mathew Vincent of ACT on hESC derived RPE cells - at Stem Cells USA

Related Post

Comments are closed.

Archives